<DOC>
	<DOCNO>NCT02324842</DOCNO>
	<brief_summary>Specific Aim 1.To examine whether combination liraglutide plus canagliflozin prevent increase HGP follow institution canagliflozin therapy produce additive even synergistic effect lower plasma glucose concentration A1c . Specific Aim 2 : To examine whether combination therapy liraglutide plus canagliflozin produce additive , even synergistic , effect promote weight loss reduction hepatic visceral fat content . Specific Aim 3 . To examine whether combination therapy liraglutide plus canagliflozin produce additive even synergistic effect reduce systolic/diastolic blood pressure 24-hour integrated blood pressure .</brief_summary>
	<brief_title>Effect Combined Incretin-Based Therapy Plus Canagliflozin Glycemic Control Compensatory Rise Hepatic Glucose Production Type 2 Diabetic Patients</brief_title>
	<detailed_description>Specific Aim 1.To examine whether combination liraglutide plus canagliflozin prevent increase HGP follow institution canagliflozin therapy produce additive even synergistic effect lower plasma glucose concentration A1c . We examine hypothesis compare effect administration liraglutide alone , canagliflozin alone , combination liraglutide plus canagliflozin : ( ) rate HGP ; ( ii ) decrease fast plasma glucose concentration ; ( iii ) counter-regulatory hormone response ( iv ) A1c . We anticipate addition liraglutide canagliflozin prevent increase plasma glucagon concentration , augment insulin secretion , blunt/block increase HGP response canagliflozin , result great decrease fast plasma glucose concentration A1c observe therapy alone . Specific Aim 2 : To examine whether combination therapy liraglutide plus canagliflozin produce additive , even synergistic , effect promote weight loss reduction hepatic visceral fat content . Specific Aim 3 . To examine whether combination therapy liraglutide plus canagliflozin produce additive even synergistic effect reduce systolic/diastolic blood pressure 24-hour integrated blood pressure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Male female subject age 1870 Subjects Type 2 Diabetes Mellitus ( T2DM ) Drug naïve stable dose ( 3 month ) metformin Have HbA1c level ≥7.0 % &lt; 10.0 % Stable weight ( ± 3 lb ) precede 3 month Subjects take drug know affect glucose metabolism ( metformin ) exclude . Individuals evidence proliferative diabetic retinopathy plasma creatinine &gt; 1.4 female &gt; 1.5 male eGFR &lt; 60 ml/min.172m2 exclude Unstable body weight ( change great ±3 lbs precede 3 month ) Participates excessively heavy exercise program</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>